FDA approves first CAR T therapy for R/R MCL

  • FDA
  • 24 Jul 2020

  • curated by Pavankumar Kamat
  • Univadis Clinical Summaries
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • The US Food and Drug Administration (FDA) has granted accelerated approval to brexucabtagene autoleucel (Tecartus) for the treatment of adults with relapsed or refractory mantle cell lymphoma (R/R MCL).
  • The recommended dose is 2×106 chimeric antigen receptor (CAR)-positive viable T cells per kilogram body weight, with a maximum of 2×108 CAR-positive viable T cells.

Why this matters

  • Brexucabtagene autoleucel is the first approved CAR T cell therapy for the treatment of R/R MCL.

Key points

  • The approval is based on data from the ongoing, single-arm ZUMA-2 pivotal trial.
  • The trial enrolled 74 patients with MCL who were previously treated with anthracycline- or bendamustine-containing chemotherapy, an anti-CD20 antibody therapy, and a Bruton tyrosine kinase inhibitor.
  • The objective response rate among patients evaluable for efficacy was 87%.
  • 62% of patients had a complete response.
  • The median duration of response has not yet been reached.
  • The most common grade 3 adverse reactions included anemia, neutropenia, thrombocytopenia, hypotension, hypophosphatemia, encephalopathy, leukopenia, hypoxia, pyrexia, hyponatremia, hypertension, infection-pathogen unspecified, pneumonia, hypocalcemia, and lymphopenia.
  • Of the patients evaluable for safety, 18% had grade 3 cytokine release syndrome and 37% had neurologic events.

For Prescribing Information, click here.